Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) had its target price dropped by analysts at The Goldman Sachs Group from $19.00 to $12.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a "neutral" rating on the stock. The Goldman Sachs Group's price objective suggests a potential upside of 23.33% from the company's current price.
Several other equities analysts have also recently issued reports on the company. Wells Fargo & Company decreased their price objective on shares of Intellia Therapeutics from $70.00 to $60.00 and set an "overweight" rating for the company in a report on Friday. Barclays decreased their price target on shares of Intellia Therapeutics from $76.00 to $55.00 and set an "overweight" rating for the company in a report on Friday, November 8th. William Blair reiterated a "neutral" rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research note on Monday, November 18th. Royal Bank of Canada reissued an "outperform" rating and issued a $54.00 target price on shares of Intellia Therapeutics in a report on Thursday, September 19th. Finally, Citigroup lowered their target price on Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating for the company in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $51.06.
Get Our Latest Analysis on NTLA
Intellia Therapeutics Stock Performance
Shares of NTLA stock traded down $0.32 during trading hours on Tuesday, hitting $9.73. 3,169,742 shares of the company were exchanged, compared to its average volume of 3,361,542. The stock has a market capitalization of $990.99 million, a price-to-earnings ratio of -1.79 and a beta of 1.83. Intellia Therapeutics has a one year low of $9.59 and a one year high of $34.87. The business's 50-day simple moving average is $13.56 and its two-hundred day simple moving average is $18.75.
Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analyst estimates of $8.28 million. The company's quarterly revenue was down 24.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.38) EPS. As a group, analysts anticipate that Intellia Therapeutics will post -5.12 EPS for the current fiscal year.
Insider Activity at Intellia Therapeutics
In other news, CEO John M. Leonard sold 26,807 shares of the company's stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares in the company, valued at $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders sold 28,735 shares of company stock worth $349,909 in the last 90 days. Corporate insiders own 3.20% of the company's stock.
Institutional Investors Weigh In On Intellia Therapeutics
Hedge funds and other institutional investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC grew its stake in shares of Intellia Therapeutics by 763.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company's stock worth $39,000 after purchasing an additional 1,550 shares during the last quarter. Eastern Bank bought a new stake in Intellia Therapeutics during the third quarter worth approximately $41,000. Values First Advisors Inc. acquired a new position in Intellia Therapeutics in the third quarter worth approximately $54,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Intellia Therapeutics by 27.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company's stock valued at $77,000 after buying an additional 794 shares in the last quarter. Finally, KBC Group NV lifted its position in shares of Intellia Therapeutics by 37.3% during the 3rd quarter. KBC Group NV now owns 3,753 shares of the company's stock valued at $77,000 after acquiring an additional 1,020 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.
About Intellia Therapeutics
(
Get Free Report)
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
Read More
Before you consider Intellia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.
While Intellia Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
